Additionally, the 36-month beta value for NBY is 2.00. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NBY is 29.36M and currently, short sellers hold a 0.40% ratio of that float. The average trading volume of NBY on April 08, 2024 was 3.65M shares.
NBY) stock’s latest price update
The stock price of Novabay Pharmaceuticals Inc (AMEX: NBY) has dropped by -7.12 compared to previous close of 0.10. Despite this, the company has seen a fall of -10.49% in its stock price over the last five trading days. Business Wire reported 2024-03-25 that EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers.
NBY’s Market Performance
NBY’s stock has fallen by -10.49% in the past week, with a monthly drop of -33.97% and a quarterly drop of -47.89%. The volatility ratio for the week is 6.01% while the volatility levels for the last 30 days are 8.19% for Novabay Pharmaceuticals Inc The simple moving average for the past 20 days is -25.74% for NBY’s stock, with a -75.41% simple moving average for the past 200 days.
Analysts’ Opinion of NBY
Many brokerage firms have already submitted their reports for NBY stocks, with Ladenburg Thalmann repeating the rating for NBY by listing it as a “Buy.” The predicted price for NBY in the upcoming period, according to Ladenburg Thalmann is $1.10 based on the research report published on September 18, 2019 of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NBY reach a price target of $4. The rating they have provided for NBY stocks is “Buy” according to the report published on July 06th, 2018.
Laidlaw gave a rating of “Buy” to NBY, setting the target price at $8 in the report published on November 15th of the previous year.
NBY Trading at -33.84% from the 50-Day Moving Average
After a stumble in the market that brought NBY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.18% of loss for the given period.
Volatility was left at 8.19%, however, over the last 30 days, the volatility rate increased by 6.01%, as shares sank -33.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.36% lower at present.
During the last 5 trading sessions, NBY fell by -10.68%, which changed the moving average for the period of 200-days by -87.67% in comparison to the 20-day moving average, which settled at $0.1241. In addition, Novabay Pharmaceuticals Inc saw -53.97% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NBY
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.54 for the gross margin
The net margin for Novabay Pharmaceuticals Inc stands at -0.79. The total capital return value is set at -1.05. Equity return is now at value -139.03, with -75.81 for asset returns.
Based on Novabay Pharmaceuticals Inc (NBY), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -1.47.
Currently, EBITDA for the company is -4.8 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 0.17. The receivables turnover for the company is 19.39for trailing twelve months and the total asset turnover is 1.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In conclusion, Novabay Pharmaceuticals Inc (NBY) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
